Concepedia

Mary Hobart

MH

Statistics

Publications

29

Citations

2K

H-Index

19

Active since

1999

Affiliations

Otsuka (United States)(Current)

Lundbeck (Denmark)

University of Pennsylvania

University of Nevada, Las Vegas

Otsuka Pharmaceutical (Spain)

Mary Hobart is an author at Otsuka (United States) specializing in psychopharmacology, pharmacotherapy, and pharmacology.

Publications per year

1999–2025

29

Publications

29

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia

John M. Kane, Aleksandar Skuban, John Ouyang et al. · Schizophrenia Research · 2015 · 326 citations

, , +10

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial

Christoph U. Correll, Aleksandar Skuban, John Ouyang et al. · American Journal of Psychiatry · 2015 · 184 citations

, , +17

Repeatable Battery for the Assessment of Neuropsychological Status as a Screening Test in Schizophrenia, II: Convergent/Discriminant Validity and Diagnostic Group Comparisons

Mary Hobart, Richard W. Goldberg, John J. Bartko et al. · American Journal of Psychiatry · 1999 · 181 citations

, , +17

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder

Michael E. Thase, James M. Youakim, Aleksandar Skuban et al. · The Journal of Clinical Psychiatry · 2015 · 178 citations

, , +17

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants

Michael E. Thase, James M. Youakim, Aleksandar Skuban et al. · The Journal of Clinical Psychiatry · 2015 · 164 citations

, , +17

1–5 of 29